3TR – Taxonomy, Treatment, Targets and Remission (Taxonomie, Behandlung, Targets und Remission)

Innovative Medicines Initiative (IMI)

The DRFZ is partner of the largest-ever Innovative Medicine Initiative 2 (IMI2) immunology project to improve disease management of non-responders to therapy across seven immune-mediated diseases called Taxonomy, Treatment, Targets and Remission (3TR): Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions.

About 3TR

Many patients with autoimmune, inflammatory and allergic diseases do not respond well or at all to current treatments. Despite their diverse symptoms, these diseases have some molecular patterns in common, suggesting that patients with different diseases may share some markers that predict the likelihood of treatment response and disease progression. Aim of 3TR is to shed new light on the factors that determine whether or not a patient is likely to respond to a given treatment.

3TR brings together 69 partner organizations from 15 European member states including academic and research institutions, small and medium-sized enterprises (SME) and pharmaceutical companies.

In the frame of about 50 clinical trials, patient samples before, during and after treatment are analysed using state-of-the-art methods. All data is added to a centralised data management platform.

The project is supported with a funding of over € 80 million from the Innovative Medicines Initiative 2 (IMI2), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Role of DRFZ  within 3TR

Within WP1 and WP4 of the 3TR project the DRFZ provides its expertise on high-throughput microbiota analysis by high-resolution microbiota cytometry, high-dimensional single cell analysis and immune monitoring as well as the knowledge of the etiopathology of chronic inflammation.